TRex Bio focuses on drug discovery and development using a human tissue-based Deep Biology Platform to identify therapeutics for immune-mediated diseases.

TRex Bio

TRexBio | 8,356 followers on LinkedIn. Decoding Human Tissue Biology to Create Revolutionary Therapeutics | TRexBio is a discovery stage biotechnology company leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us to identify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis.

Executive Director @ TRex Bio | Computational Biology, Functional Genomics, Informatics

Christopher Yohn, Ph.D.

Partner - Pfizer Ventures

Michael Baran

Global Human Resources Leader

Michelle E.

Edith Rodriguez

TRexBio

We’re thrilled to announce the close of our $84 million Series B financing round, led by Delos Capital, with participation from new investors Avego BioScience Capital and Agent Capital as well as ongoing support from our existing investors, Eli Lilly and Company, SV Health Investors, Pfizer Ventures, Johnson & Johnson Innovation - JJDC, Inc., Alexandria Venture Investments, and Polaris Partners. A huge thank you to all our investors for their belief in our vision and our commitment to transforming autoimmune and inflammatory disease treatment. We look forward to advancing our lead drug candidate TRB-061, a novel TNFR2 agonist, into clinical trials next year. Read the release here: https://lnkd.in/ez6is6pY

TRexBio’s COO Laura Berner recently joined the hosts of the Women @ RopesTalk podcast to discuss her own career path in biopharma, her views on the next stages of growth for TRexBio, and the career advice that’s resonated with her. Listen here: https://lnkd.in/eTSmJzPq

We are proud to announce that our collaboration partner Eli Lilly and Company has initiated a phase 1 first-in-human study of TRB-051 for autoimmune and inflammatory diseases. This is the first program to enter the clinic under the Research and Collaboration Agreement between TRexBio and Lilly announced in early 2023. Read more here: https://lnkd.in/eFGNpy66 #immunology #autoimmunity #inflammation

TRexBio was proud to join industry and academic leaders at the 6th annual Treg-Directed Therapies Summit last week in Boston. Chief Scientific Officer Melanie Kleinschek , DVM, PhD presented on our Deep Biology Platform and the way we leveraged it to uncover the molecular details of TNFR2 agonism on #Treg . These insights led to our development of TRB-061, a novel TNFR2 agonist for the treatment of inflammatory and autoimmune disease. IND-enabling studies with TRB-061 are ongoing, and first-in-human studies are anticipated in 2025. #DeepBiology #immunology #autoimmunity #inflammation

Principal Scientist Robin Aglietti presented on behalf of TRexBio at the #PEGSummit in Boston this week. She discussed TRB-061, a novel agonist for TNFR2, a target highly expressed on immunosuppressive #Treg . Our interrogation of TRB-061 supports its broad potential for the treatment of autoimmune and inflammatory diseases. IND-enabling studies are ongoing, and first-in-human studies with TRB-061 are anticipated in 2025. #PEGSummit #Treg #Immunology #DeepBiology

The TRexBio team was well represented at the joint Keystone meeting for Innate Immunity and Systems and Engineering Immunology held last week in Banff. First, we presented a poster on our #DeepBiology platform at the Innate Immunity portion of the meeting. We discussed the TRexBio approach for identifying novel targets and creating tissue #Treg -focused therapeutics for immune-mediated diseases. Our platform does this by combining human tissue biology, high throughput omics, advanced computational tools, and translational immunology. Next, at the Systems and Engineering Immunology portion of the meeting, we presented a poster on TNFR2 biology and its relevance to dysregulated tissue Treg. Our interrogation of TNFR2 led to an understanding of key signaling pathways, and this in turn formed the basis for a translational framework for therapeutic invention. TRexBio applied this in the development of TRB-061, our novel TNFR2 agonist for the treatment of inflammatory disease; First-in-human studies with TRB-061 are planned for early 2025. Kudos to Jovanny Guillen , Ian Taylor , and the rest of the TRexBio team for their work! #KSInnateImmune24 #KSSystemsImmune24 #Treg #Immunology #DeepBiology

Today we announced that Johnson & Johnson Innovative Medicine has exercised its first option for an exclusive license to develop and commercialize a program directed to a novel target for immunology and inflammation arising out of our collaboration. "This success further validates the power of our platform to produce scientifically attractive programs," said Laura Berner , COO. "Alongside our productive pharma collaborations, we remain focused on advancing our own pipeline of programs with the goal of bringing durable clinical benefit to patients suffering from immune mediated diseases." Read more here: https://lnkd.in/eQUqzxQN #Treg #Tcellbiology #immunology #DeepBiology

Happy holidays from all of us at TRexBio! #Treg #Tcellbiology #immunology #DeepBiology

TRexBio is excited to announce that Michael Townsend has joined as our new VP, Head of Translational Biology! Welcome to the TRexBio team! #Treg #Tcellbiology #immunology #DeepBiology

TREX

BIO:TREX

TRex Bio